TEACHER
- Organizing Committee Members
- International Committee
- 2024 Company Presentations
- Plenary Session 1 – Global Biotech Development
- Plenary Session 2 – Global Biotech Development
- Plenary Session 3 – The Value of Innovation for a Healthier Taiw
- Session A-1 – New Therapeutic Modalities
- Session A-2 – Gene and Cell Therapies- Advanced Manufacture and
- Session A-3 – AI & Translational Medicine
- Session A-4 – Taiwan BIO Awards-Successful Stories
- Session A-5 – CMC Program Design: Pioneering Biologics Developme
- Session A-6 – Innovative Developments and Cross-Disciplinary App
- Session A-7 – Innovative Developments and Cross-Disciplinary App
- Session A-8 – Novel ADC-based Target Therapy
- Session A-9 – Smart HealthCare
- Session A-10 – Global Trends and Clinical Applications of Whole
- Session A-11 – Special Session: Digital Health
- Investment Summit Session B - 1
- Investment Summit Session B - 2
- Regional Collaboration Forum-Thailand
- Regional Collaboration Forum-Malaysia
- Satellite Symposia
David Chang
Session A-2 – Gene and Cell Therapies- Advanced Manufacture and Beyond
Date：23 July
Time：16:00 – 16:05, 17:25 – 17:30 (GMT+8)
David Chang
CEO
Taiwan Bio-Manufacturing Corporation
◆ Experiences
President and CEO, WuXi Advanced Therapy Unit
June 2020 – February 2024
Corporate VP, Head of Cell Therapy Manufacturing, Celgene (now BMS)
August 2018 – June 2020
Corporate VP, Global Head of Technical Operations, Roche
September 2013 – August 2018
Senior Director of Biologics Manufacturing Science and Technology, Genentech
June 2006 – September 2013
Director, Head of Cell Culture Process Development, Biogen
September 2000 – June 2006
Senior Scientist of Cell Culture, BASF Research
May 1997 – September 2000
Senior Chemical Engineer of Cell Culture, Schering-Plough Research Institute
June 1992 – May 1997
◆ Education
PhD, Biochemical Engineering, MIT (1987–1992)
B.S., Chemical Engineering, NTU (1981–1985)
Speech title & Synopsis
Opening Remarks & Panel Discussion
as Moderator in Panel Discussion
